Chemogenomics: An emerging strategy for rapid target and drug discovery

Nature Reviews Genetics

Volumn 5, Issue 4, 2004, Pages 262-275

  Bredel, Markus ^a,b   Jacoby, Edgar ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BR 1; BR 6; CDK 731; CYCLOSPORIN A; DES 121 123; DOPAMINE RECEPTOR BLOCKING AGENT; FR 901228; H 8A; JANSSEN 1; K 252A; KETANSERIN; KF 25706; KISSEI 1; KT 8529; N 68A; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEW DRUG; NSC 65828; PEPTIDE DERIVATIVE; PROPRANOLOL; R 5A; RADICICOL; RO 16814; SEROTONIN AGONIST; TACROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

BIOINFORMATICS; CANCER RESEARCH; CHEMOGENOMICS; DNA LIBRARY; DRUG DETERMINATION; DRUG TARGETING; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; PHARMACOGENOMICS; PHYLOGENY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; GENOMICS; HUMANS; PHARMACOGENETICS;

EID: 1842532337     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1317     Document Type: Review

References (144)

1. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
2. Drews, J. Genomic sciences and the medicine of tomorrow. Nature Biotechnol. 14, 1516-1518 (1996).
3. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
4. Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
5. Kim, J. A. Targeted therapies for the treatment of cancer. Am. J. Surg. 186, 264-268 (2003).
6. Wolcke, J. & Ullmann, D. Miniaturized HTS technologies - uHTS. Drug Discov. Today 6, 637-646 (2001).
7. Stockwell, B. R., Haggarty, S. J. & Schreiber, S. L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6, 71-83 (1999).
8. Stockwell, B. R. Chemical genetics: ligand-based discovery of gene function. Nature Rev. Genet. 1, 116-125 (2000).
9. Stockwell, B. R. Frontiers in chemical genetics. Trends Biotechnol. 18, 449-455 (2000).
10. Walters, W. P. & Namchuk, M. Designing screens: how to make your hits a hit. Nature Rev. Drug Discov. 2, 259-266 (2003).
11. Entzeroth, M. Emerging trends in high-throughput screening. Curr. Opin. Pharmacol. 3, 522-529 (2003).
12. Muller, O. et al. Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening. Angew. Chem. Int. Ed. Engl. 43, 450-454 (2004).
13. Shoemaker, R. H. et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr. Top. Med. Chem. 2, 229-246 (2002).
14. Pantoliano, M. W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429-440 (2001).
15. Shin, Y. G. & van Breemen, R. B. Analysis and screening of combinatorial libraries using mass spectrometry. Biopharm. Drug Dispos. 22, 353-372 (2001).
16. Muckenschnabel, I., Falchetto, R., Mayr, L. M. & Filipuzzi, I. SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. Anal. Biochem. 324, 241-249 (2004).
17. Chan, T. F., Carvalho, J., Riles, L. & Zheng, X. F. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc. Natl Acad. Sci. USA 97, 13227-13232 (2000).
18. Griffith, E. C. et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4, 461-471 (1997).
19. Sin, N. et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl Acad. Sci. USA 94, 6099-6103 (1997).
20. Zewail, A. et al. Novel functions of the phosphatidylinositol metabolic pathway discovered by a chemical genomics screen with wortmannin. Proc. Natl Acad. Sci. USA 100, 3345-3350 (2003).
21. Marton, M. J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4, 1293-1301 (1998). Describes an approach based on genome-wide gene-expression patterns to identify the immediate pathways that are altered by a drug and to detect drug effects that are mediated by unintended targets.
22. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
23. Kwon, H. J. Chemical genomics-based target identification and validation of anti-angiogenic agents. Curr. Med. Chem. 10, 717-736 (2003).
24. Carr, R. & Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discov. Today 7, 522-527 (2002).
25. Bleicher, K. H. Chemogenomics: bridging a drug discovery gap. Curr. Med. Chem. 9, 2077-2084 (2002).
26. Jung, M., Kim, H. & Kim, M. Chemical genomics strategy for the discovery of new anticancer agents. Curr. Med. Chem. 10, 757-762 (2003).
27. Goodnow, R. A. Jr, Guba, W. & Haap, W. Library design practices for success in lead generation with small molecule libraries. Comb. Chem. High Throughput Screen. 6, 649-660 (2003). Summary of current practices In the design of compound libraries for use in drug discovery, focusing on the generation of novel structures that are amenable to rapid and efficient lead optimization.
28. Root, D. E., Flaherty, S. P., Kelley, B. P. & Stockwell, B. R. Biological mechanism profiling using an annotated compound library. Chem. Biol. 10, 881-892 (2003). Annotated compound libraries with known biological activity are introduced to guide experiments for pathway elucidation. Algorithms for the build-up of annotations from Medicine reports and for scoring statistically enriched mechanisms are also described.
29. Eguchi, M. et al. Chemogenomics with peptide secondary structure mimetics. Comb. Chem. High Throughput Screen. 6, 611-621 (2003).
30. Abel, U., Koch, C., Speitling, M. & Hansske, F. G. Modern methods to produce natural-product libraries. Curr. Opin. Chem. Biol. 6, 453-458 (2002).
31. Burke, M. D. & Schreiber, S. L. A planning strategy for diversity-oriented synthesis. Angew Chem. Int. Ed. Engl. 43, 46-58 (2004).
32. Ki, S. W. et al. Radicicol binds and inhibits mammalian ATP citrate lyase. J. Biol. Chem. 275, 39231-39236 (2000).
33. Sharma, S. V., Agatsuma, T. & Nakano, H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 16, 2639-2645 (1998).
34. Soga, S. et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 59, 2931-2938 (1999).
35. Giaever, G. et al. Chemoganomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl Acad. Sci. USA 101, 793-798 (2004). Demonstrates the efficacy of a genome-wide protocol in yeast that allows the identification of gene products that functionally interact as on- or off-targets with small molecules, thereby allowing an understanding of the in vivo response to small-molecule perturbants.
36. Han, C. K. et al. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg. Med. Chem. Lett. 10, 39-43 (2000).
37. Ueda, H., Nakajima, H., Hori, Y., Goto, T. & Okuhara, M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58, 1579-1583 (1994).
38. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
39. Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J. & Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95, 3356-3361 (1998).
40. Sandor, V. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728 (2002).
41. Piekarz, R. L. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2865-2868 (2001).
42. Marshall, J. L. et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2, 325-332 (2002).
43. Carducci, M. A. et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7. 3047-3055 (2001).
44. Gore, S. D. et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8, 963-970 (2002).
45. Nemunaitis, J. J. et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 9, 58-66 (2003).
46. Kelly, W.K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid adminstered intravenously. Clin. Cancer Res. 9, 3578-3588 (2003).
47. Nguyen, C. et al. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc. Natl Acad. Sci. USA 100, 1169-1173 (2003).
48. Weinstein, J. N. & Buolamwini, J. K. Molecular targets in cancer drug discovery: cell-based profiling. Curr. Pharm. Des. 6, 473-483 (2000).
49. Monks, A. et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83, 757-766 (1991).
50. Zheng, X. F. & Chan, T. F. Chemical genomics in the global study of protein functions. Drug Discov. Today 7, 197-205 (2002).
51. Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet. 9, 138-141 (1993).
52. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
53. Robinson, D. R., Wu, Y. M. & Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene 19, 5548-5557 (2000).
54. Dan, S. et al. Ah integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62, 1139-1147 (2002).
55. Zembutsu, H. et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Ras. 62, 518-527 (2002).
56. Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
57. Wittig, R. et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res. 62, 6698-6705 (2002).
58. Hoshida, Y. et al. Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. J. Gastroenterol. 37 (Suppl. 14), 92-95 (2002).
59. Kihara, C. et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61, 6474-6479 (2001).
60. Komatani, H. et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 61, 2827-2832 (2001).
61. Levenson, V. V., Davidovich, I. A. & Roninson, I. B. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res. 60, 5027-5030 (2000).
62. Sakamoto, M. et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum. Cell 14, 305-315 (2001).
63. Turton, N. J. et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20, 1300-1306 (2001).
64. Vikhanskaya, F., Marchini, S., Marabese, M., Galliera, E. & Broggini, M. p73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res. 61, 935-938 (2001).
65. Weldon, C. B. et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132, 293-301 (2002).
66. Watts, G. S. et al. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J. Pharmacol. Exp. Ther. 299, 434-441 (2001).
67. Duan, Z., Feller, A. J., Penson, R. T., Chabner, B. A. & Seiden, M. V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 5, 3445-3453 (1999).
68. Kudoh, K. et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166 (2000).
69. Maxwell, P. J. et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63, 4602-4606 (2003).
70. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000). This paper has pioneered the large-scale analysis of the relationship between patterns of gene expression and patterns of anticancer drug activity, thereby directly linking bioinformatics and chemoinformatics.
71. Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787-10792 (2001).
72. Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227-235 (2000).
73. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
74. Bao, L., Guo, T. & Sun, Z. Mining functional relationships in feature subspaces from gene expression profiles and drug activity profiles. FEBS Lett. 516, 113-118 (2002).
75. Moriyama, M. et al. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol. Cancer Ther. 2, 199-205 (2003).
76. Butte, A. J., Tamayo, P., Slonim, D., Golub, T. R. & Kohane, I. S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA 97, 12182-12186 (2000). Describes a method that allows a gene to be linked to several other genes as well as to phenotypic measures of drug susceptibility through the construction of a chemical genetic network.
77. Wallqvist, A., Rabow, A. A., Shoemaker, R. H., Sausville, E. A. & Covell, D. G. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol. Cancer Ther. 1, 311-320 (2002).
78. Blower, P. E. et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2, 259-271 (2002). The authors present a model that allows systematic and fluent exploration of the relationships between the structural features of a compound and global gene expression.
79. Gygi, S. P., Rochon, Y., Franza, B. R. & Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720-1730 (1999).
80. Bleicher, K. H., Bohm, H. J., Muller, K. & Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nature Rev. Drug Discov. 2, 369-378 (2003). Describes the process from hit to lead generation in a modern industrial setup and focuses on the role of quality versus quantity to improve the attrition rates at later stages of drug development.
81. Cramer, R. D., Patterson, D. E. & Bunce, J. D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res. 291, 161-165 (1989).
82. Rusinko, A., Farmen, M. W., Lambert, C. G., Brown, P. L. & Young, S. S. Analysis of a large structure/biological activity data set using recursive partitioning. J. Chem. Inf. Comput. Sci. 39, 1017-1026 (1999).
83. Nicolaou, C. A., Tamura, S. Y., Kelley, B. P., Bassett, S. I. & Nutt, R. F. Analysis of large screening data sets via adaptively grown phylogenetic-like trees. J. Chem. Inf. Comput. Sci. 42, 1069-1079 (2002).
84. Labute, P. Binary QSAR: a new method for the determination of quantitative structure actMty relationships. Pac. Symp. Biocomput. 444-455 (1999).
85. Stanton, D. T., Morris, T. W., Roychouchury, S. & Parker, C. N. Application of nearest-neighbor and duster analyses in pharmaceutical lead discovery. J. Chem. Inf. Comput Sci. 39, 21-27 (1999).
86. Hopfinger, A. J. & Duca, J. S. Extraction of pharmacophore information from high-throughput screens. Curr. Opin. Biotechnol. 11, 97-103 (2000).
87. Gedeck, P. & Willett, P. Visual and computational analysis of structure-activity relationships in high-throughput screening data. Curr. Opin. Chem. Biol. 5, 389-395 (2001).
88. Engels, M. F. Creating knowledge from high-throughput screening data. Ernst Schering Res. Found. Workshop, 87-101 (2003).
89. Raymond, J. W. & Willett, P. Maximum common subgraph isomorphism algorithms for the matching of chemical structures. J. Comput. Aided Mol. Des. 16, 521-533 (2002).
90. Roberts, G., Myatt, G. J., Johnson, W. P., Cross, K. P. & Blower, P. E. Jr. LeadScope: software for exploring large sets of screening data. J. Chem. Inf. Comput. Sci. 40, 1302-1314 (2000).
91. Agrafiotis, D. K., Lobanov, V. S. & Salemme, F. R. Combinatorial informatics in the post-genomics ERA. Nature Rev. Drug Discov 1, 337-346 (2002).
92. Lan, N., Montelione, G. T. & Gerstein, M. Ontologies for proteomics: towards a systematic definition of structure and function that scales to the genome level. Curr. Opin. Chem. Biol. 7, 44-54 (2003).
93. Stevens, R., Goble, C. A. & Bechhofer, S. Ontology-based knowledge representation for bioinformatics. Brief. Bioinform. 1, 398-414 (2000).
94. Karp, P. D. An ontology for biological function based on molecular interactions. Bioinformatics 16, 269-285 (2000).
95. Koch, M. A., Breinbauer, R. & Waldmann, H. Protein structure similarity as guiding principle for combinatorial library design. Biol. Chem. 384, 1265-1272 (2003).
96. Glen, R. Developing tools and standards in molecular informatics. Interview by Susan Aldridge. Chem. Commun. (Camb.) 2745-2747 (2002).
97. Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294-295 (2003).
98. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet. 25, 25-29 (2000).
99. Ji, Z. L. et al. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Saf. 26, 685-690 (2003).
100. Sun, L. Z., Ji, Z. L., Chen, X., Wang, J. F. & Chen, Y. Z. ADME-AP: a database of ADME associated proteins. Bioinformatics 18, 1699-1700 (2002).
101. Ji, Z. L. et al. Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME. Drug Discov. Today 8, 526-529 (2003).
102. Chen, X., Ji, Z. L. & Chen, Y. Z. TTD: Therapeutic Target Database. Nucleic Acids Res. 30, 412-415 (2002).
103. Caron, P. R. et al. Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5, 464-470 (2001).
104. Mitchison, T. J. Towards a pharmacological genetics. Chem. Biol. 1, 3-6 (1994).
105. Zheng, X. F. & Chan, T. F. Chemical genomics: a systematic approach in biological research and drug discovery. Curr. Issues Mol. Biol. 4, 33-43 (2002).
106. Sehgal, A. Drug discovery and development using chemical genomics. Curr. Opin. Drug Discov. Devel. 5, 526-531 (2002).
107. Pearson, W. R. & Lipman, D. J. Improved tools for biological sequence comparison. Proc. Natl Acad. Sci. USA 85, 2444-24448 (1988).
108. Duckworth, D. M. & Sanseau, P. In silico identification of novel therapeutic targets. Drug Discov. Today 7, S64-S69 (2002).
109. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
110. Lehmann, J. et al. Redesigning drug discovery. Nature 384 (Suppl.), 1-5 (1996)
111. Murcko, M. & Caron, P. Transforming the genome to drug discovery. Drug Discov. Today 7, 5583-5134 (2002).
112. Schuffenhauer, A., Floersheim, P., Acklin, P. & Jacoby, E. Similarity metrics for ligands reflecting the similarity of the target proteins. J. Chem. Inf. Comput. Sci. 43, 391-405 (2003).
113. Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy - application to G protein-coupled receptors. Quantitative Structure-Activity Relationships 20, 115-123 (2001).
114. New, D. C., Miller-Martini, D. M. & Wong, Y. H. Reporter gene assays and their applications to bioassays of natural products. Phytother. Res. 17, 439-448 (2003).
115. Boland, M. V. & Murphy, R. F. Automated analysis of patterns in fluorescence-microscope images. Trends Cell Biol. 9, 201-202 (1999).
116. Frye, S. V. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol. 6, R3-R7 (1999). This fundamental article introduces the 'structure-activity relationship homology' concept, which is the baseline for carrying out target-family reverse chemogenomics.
117. Krejsa, C. M. et al. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Devel. 6, 470-480 (2003).
118. Bajorath, J. Integration of virtual and high-throughput screening. Nature Rev. Drug Discov. 1, 882-894 (2002). This review article covers the current concepts that are involved in integrating both virtual and high-throughput screening.
119. Langer, T. & Krovat, E. M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Devel. 6, 370-376 (2003).
120. Xue, L. & Bajorath, J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen. 3, 363-372 (2000).
121. Glen, R. C. & Allen, S. C. Ligand-protein docking: cancer research at the interface between biology and chemistry. Curr. Med. Chem. 10, 763-767 (2003).
122. Abagyan, R. & Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 5, 375-382 (2001).
123. Jenkins, J. L. & Shapiro, R. Identification of small-molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking. Biochemistry 42, 8674-6687 (2003).
124. Schapira, M. et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc. Natl. Acad. Sci. USA 100, 7354-7359 (2003).
125. Vangrevelinghe, E. et al. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46, 2656-2662 (2003).
126. Schneider, G. & Bohm, H. J. Virtual screening and fast automated docking methods. Drug Discov. Today 7, 64-70 (2002).
127. Lamb, M. L. et al. Design, docking, and evaluation of multiple libraries against multiple targets. Proteins 42, 296-318 (2001).
128. Chen, X., Ung, C. Y. & Chen, Y. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat. Prod. Rep. 20, 432-44 (2003). Describes the application of high-throughput docking for identifying drug targets in an automated fashion. The entire PDB protein structure repertoire Is docked against selected natural products. Predictions for their mechanism of action are successfully made.
129. Gunther, J., Bergner, A., Hendlich, M. & Klebe, G. Utilising structural knowledge in drug design strategies: applications using Relibase. J. Mol. Biol. 326, 621-636 (2003).
130. Michalovich, D., Overington, J. & Fagan, R. Protein sequence analysis in silico: application of structure-based bioinformatics to genomic initiatives. Curr. Opin. Pharmacol. 2, 574-580 (2002).
131. Jacoby, E., Schuffenhauer, A. & Floersheim, P. Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect. 16, 93-102 (2003).
132. Schuffenhauer, A. et al. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42, 947-955 (2002). Provides a foundation for linking the fields of chemoinformatics and bioinformatics by establishing ligand-discovery ontologies. The application for similarity searching and focused library design are highlighted.
133. Meng, L., Kwok, B. H., Sin, N. & Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59, 2798-2801 (1999).
134. Kino, T. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 40, 1256-1265 (1987).
135. Kino, T. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40, 1249-1255 (1987).
136. Mirzoeva, S. et al. Screening in a cell-based assay for inhibitors of microglial nitric oxide production reveals calmodulin-regulated protein kinases as potential drug discovery targets. Brain Res. 844, 126-134 (1999).
137. Barrie, S. E. et al. High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Anal. Biochem. 320, 66-74 (2003).
138. Lukas, T. J., Mirzoeva, S., Slomczynska, U. & Watterson, D. M. Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J. Med. Chem. 42, 910-919 (1999).
139. Liu, Y. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837-846 (2003).
140. Wittich, S. et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 45, 3296-3309 (2002).
141. Mai, A. et al. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J. Med. Chem. 45, 1778-1784 (2002).
142. Kao, R. Y. et al. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc. Natl Acad. Sci. USA 99, 10066-10071 (2002).
143. Jenkins, J. L., Kao, R. Y. & Shapiro, R. Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin. Proteins 50, 81-93 (2003).
144. Efferth, T. et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64, 382-394 (2003).